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Summary: A new commercially available CEA immunoassay, using monoclonal antibody, was evaluated for
the purpose of routine clinical use.
The between-day coefficient of Variation was 5.2% at the 6.6 g/l level and 4.1% at the 14.2 g/l level.
The results of analysis of sera from 260 patients were compared with the data from an established method
with polyclonal antiserum. A good correlation between the two methods was found.
When the patients were classified according to groups with known types of carcinomas no systematic
differences between the monoclonal and polyclonal modes of assay were apparent.
Relatively large differences in serum CEA levels did occur in individuäl patients necessitating a transition
period in changing from one method to the other.
Vergleich von Enzymimmünoassays mit monoklonalen und polyklonalen Antikörpern für carcinoembryonales
Antigen
Zusammenfassung: Ein neuer kommerziell erhältlicher Immunoassay for carcinoembryonales Antigen, der
einen monoklonalen Antikörper verwendet, wurde hinsichtlich seines Einsatzes in der klinischen Routine
geprüft.
, «
Die Impräzision von Tag zu Tag betrug bei 6,6 g/l 5,2% und bei 14,2 g/l 4,1%. Die Ergebnisse der
Untersuchung von Seren von 260 Patienten würden mit den Werten verglichen, die mit der gebräuchlichen
Methode mit polyklonalen Antikörpern erhalten wurden. Zwischen beiden Methoden bestand eine gute
Korrelation.
Nach Klassifizierung der Patienten in Gruppen mit bekannten Typen von Carcinomen wurden keine systema-
tischen Differenzen zwischen den beiden Bestimmungsarten gefunden.
Relativ große Unterschiede in den Konzentrationen von carcinoembryonalem Antigen traten bei einzelnen
Patienten auf, was eine Übergangsperiode beim Wechsel von der einen Methode zur anderen erfordert.
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Introduction
The measurement of carcinoembryonic antigen
(CEA) in serum has become an important routine
Parameter in the postoperative management of cer-
tain malignant diseases especially of mammary cancer
and of carcinomas of the digestive tract (l, 2, 3).
In previous years CEA was measured in the authors'
laboratory with an enzyme-immunoassay (EIA) from
Abbott Diagnostics (Abbott, Amstelveen, The Ne-
therlands) using a polyclonal guinea pig antibody (4,
5).
A disruption of the supply of this reagent to our
country prompted us to consider an alternative mode
of assay. Röche Diagnostics (Hoffmann-La Röche,
Mijdrecht, The Netherlands) in 1983 introduced a
solid phase EIA according to the Sandwich principle.
The method uses monoclonal mouse antibody against
CEA coated on polystyrene beads. The second anti-
body is a goat anti-CEA conjugated to peroxidase.
o-Phenyle^ediamine serves äs the chromogenic sub-
strate, the resulting colour being spectrophotometri-
cally measured at 492 nm. Because of the limited
published literature on this method (6), we investi-




Blood was taken by punction from an antecubital vein into
evacuated blood collecting tubes. The sera were frozen at
— 20 °C until assay. The samples originated from two hundred
and sixty (260) unselected patients for whom a CEA determina-
tion had been requested by their physicians.
On one or more occasions, 325 blood samples were collected
from the total group.
The patient group consisted of 64% males and 36% of females.
The age ränge of the males was 44—89 years, with an arithmetic
mean of 66.1 and a median value of 68.5 years. The age ränge
of the females was 24—88 years, with an arithmetic mean of
65.8 and a median value of 66.7 years. A clinical diagnosis was
available in 170 cases.
Clinically and histologically proven malignant disease was pre-
sent in 112 patients (tab. 1).
The remainder showed various pathologies (diverticulitis
(n = 10), diverticulosis (n = 5), polyposis coli (n = 3), ulcus
ventriculi (n = 2) or no clearly abnormal findings (n = 38)).
CEA assay
The r patient samples were assayed in duplicate by both the
polyclonal EIA from Abbott and the new monoclonal EIA
from Röche. The detailed instructions of the manufaeturers
were followed (tab. 2). Briefiy, both methods consist of a heat-
inactivation step of the sample followed by the immunological
reactions.
Tab. 1. Distribution of carcinomas in the present study.
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*) A 4 h protocol also became available upon completion of
the manuscript, and a l h protocol became available in the
USA.
In the Abbott assay use was made of two incubation periods
of two hours, in the Röche assay a single overnight incubation
step was used. After this incubation the boünd peroxidase label
converts the Substrate o-phenylenediamine into 2,2-diamino-
azobenzene, which is spectrophotometrically measured at
492 nm.
A calibration graph is prepared by use of the CEA Standards
included in each kit.
In order to study the precision of the Röche method three
batches of the Röche reagent with different lot numbers (a, b,
c) were used. Pools of fresh patient sera were prepared, divided
into portions and kept frozen until the assay date at —20 °C.
Within-day precision was obtained by analysis of ten replicate
samples of each pool. The concentrations of CEA used are
indicated in the ,results section'.
Between-day precision was calculated from the results obtained
with two pool sera.
These were assayed in duplicate on ten different days spread
over a two-month period together with the control material
supplied with the kit. r.
The linearity of the Röche assay was studied by analysing
dilutions of 3 human sera with CEA concentrations below 20
§/1. The samples were diluted with the zero Standard of the
kit»to 10, 20, 40, 60, 80% of the original concentrations. This
consists of a 0.2 mmol/1 acetate bu$er at pH 5.0.
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In addition, ten sera of high CEA concentration (approximate
ränge 200—1500 g/l) were diluted with the zero Standard. For
each sample different degrees of dilution were applied, resulting
in concentrations within the measuring ränge.
For instance, suppose one of the sera contained a CEA concen-
tration of 360 g/l. After being diluted twenty, forty and eighty
times the sample should ideally show concentrations of 18, 9
and 4.5 g/l respectively. In order to obtain the relative recover-
ies the concentration calculated by using the largest dilution
was arbitrarily taken äs one hundred percent for each sample.
Four of these sera were also diluted with human zero serum in
the same way. This zero serum consisted of a pool of samples
in which previous assays had shown CEA concentrations less
than 0.5 g/l.
Results
Precision of the Röche assay
The coefficient of Variation (CV) for measurement of
CEA in the individual tubes within the series ranged
between 2.3 and 10%. By taking the square root of
these figures the CV for a CEA assay performed in
duplicate was obtained. It ranged from 1.5 to 3.2%
within the day (tab. 3).
Table 4 shows the reproducibility of the assay using
duplicate samples over a two-month period. CVs of
approximately 5% were obtained. It was observed
that calculation over a longer period gave rise to
larger values for the CV. For example, over a four-
Tab. 3. Within-series precision of Röche CEA method.
Lot Mean Variation coefficient (%)*)

































*) Number of replicates is ten for all exjjeriments.












month period, CVs of 11% and 12% respectively can
be calculated for the two pool sera of table 4. The
larger CVs at long term were due to an apparent
decrease of immunoreactive CEA concentration dur-
ing storage of our samples at -20 °C. This downward
'drift was about 15% from the original values over a
four to six-month period. It was visible with all our
frozen control sera, both with the Röche and Abbott
assays.
Linearity of Röche assay
The actual concentrations found for the sera diluted
with the zero Standard solution of the kit were plotted
against the values theoretically expected (not shown).
Linear graphs were obtained within the measuring
ränge of the assay (0 — 20 g/l).
Furthermore the deviations of the individual points
from the graphs were within the precision limits of
the assay indicated by table 3.
Sera with high CEA concentrations were diluted to
different degrees ranging from 10, 20 and 40 times
to 100, 200 and 400 times, in order to achieve values
within the measuring ränge.
The various dilutions with the zero Standard of the
kit resulted in approximately identical concentrations
after correction for the dilution factors applied. The
relative recoveries of the diluted samples ranged from
93 to 120%. A mean recovery of 98% ± 9 (l SD)
was obtained.
The dilutions with human pool serum yielded lower
values for the apparent CEA concentrations in com-
parison with the same samples diluted with the zero
Standard of the kit. The relative recoveries ranged
from 83 to 92%. The mean recovery was 89 ± 4%
(l SD).
Correlation between Röche monoclonal EIA
and Abbott polyclonal EIA
Graphs comparing the CEA serum concentrations
obtained with the two methods are shown in figure
1. The corresponding data from linear regression
analysis are given in table 5.
Tab. 5. Correlation between monoclonal EIA from Röche (y)
and polyclonal EIA from Abbott (x).








samples (p < 0.05)
294 r = 0.948




y = 0.999 - 0.003
y = 1.05 x -H 0.146
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Fig. 1. Comparison of CEA concentrations in human sera found with the polyclonal enzyme immunoassay from Abbott and
the monoclonal enzyme immunoassay from R che. The pictures have been taken directly from Computer plots. On the
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Fig. 2. Comparison of CEA concentrations from patients with
known types of carcinoma. No systematic differences
between the two assays can be discerned. See text for
further explanation.
Type of carcinoma:
n small cell lung c.
e squamous c. lung
α rectum c.
o colon c.


















It can be seen that the line of best fit passes through
the origin and, for practical purposes, does not differ
from the line described by the relationship y = x.
Six sets of patient data were not included in figure l
because of very high vahies for CEA. These were
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1230 and 720,4000 and 6500,1500 and 2150,455 and
580,1150 and 1900 and 500 and 460 §/1, according to
the Abbott and Röche assays, respectively.
A subdivision into known types of carcinomas is
presented in figure 2. The CEA levels above 10 g/l
are given separately in table 6.
Visual inspection of the data shows no systenaatic
overall difference between the polyclonal and mono-
clonal assay for any type of tumour. The differences
between the two assays in the individual patient were
consistent with time. Thus the Röche method yielded
either lower, the same or higher values, compared





Fig. 3. Typical plots of CEA concentrations in varipus cases
of pathology followed against time. The differences




Case Ä: patient with adenpcarcinoma öf stomach. At
first subtotal stomach resection was applied fpr, fol-
lowed by chemotherapy. Ät the end, progressive disease
with metastases to liver and lymph nodes is present.
Case B: patient with adenocarcinoma pf stomach.
Status after partial resection and adjuvant chemother-
apy. Progressive disease.
Case C: patient with adenocarcinoma of coecum, for
which a hemicolectomy was performed in the past.
Guided by rising CEA level, a right liver lobe metastase
was found. The CEA level feil after metastasectomy.
Case D: patient with epidermoid cell carcinoma of cer-
vix and endometrium with lymph metastases. Treatment
with cytostatic agents and radiation therapy.
Case E: patient with adenocarcinoma of right lung.
Status after lobectomy.
Discussion
A coefficient of Variation of 5% was found with
the Röche assay. This between-day reproducibility
compares favourably with previously published data
on CEA assays. CVs of 5 —15% have been reported
(4,5,7). .
This good precision may be explained in part by the
high actual absorbance values obtained during the
spectrophotometric measurement. An absorbance of
about 1.5 was obtained at a CEA concentration of
20 g/l, compared with about 0.6 in the Abbott assay.
A small but consistent difference was observed be-
tween CEA serum values obtained with different di-
luting fluids. After dilution with human serum, the
apparent recovery was about 10% lower than after
dilution with acetate buffer, pH 5, from the Röche
kit.
This matrix effect may be due to the composition of
normal serum or to protein concentration alone. With
respect to the latter factor, Kim et al. reported de-
creasing CEA values when the concentration of bo-
vine serum albumin in their extraction solution was
increased to 5 g/l (8).
Theoretically this has implications in cases of rising
CEA levels during the course of the disease. Suppose
a patient's CEA level changes from a level below 20
g/l to above this threshold value. The sample is
assayed without a diluent below 20 g/l and is diluted
with buffer above this level.
Thereföre a discontinuous increase upon the actual
increment would occur. However in the opinion of
the authors this seems to be no serious disadvantage
of the Röche method for routine purposes. Firstly
the difference between buffer and serum äs diluting
fluids is relatively small, compared with the large
increases of CEA concentration actually occurring in
progressive disease states, see e.g. figure 3.
Secondly, the number of patients concerned is rela-
tively small compared with the large group below 20
§/1, e. g. see figure l. Nevertheless more experiments
would be necessary to settle this point in detail.
The 45 degree slope of the regression line (fig. 1)
implies that there is no systematic bias between the
results obtained with the two methods in patient sera.
Thereföre we decided to keep the same reference
interval (95% confidence limit) for the Röche assay
äs in use for the Abbott assay, i. e. up to 4.5 g/l (5).
One of the arguments for changing from an assay
using a polyclonal antibody to one with a monoclonal
antibody could be the expectation of greater speci-
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ficity and/or sensitivity for particular types of tu-
mours.
Rogers et al. (9) described a monoclonal antibody
with a preference for CEA in the serum of stomach
carcinoma patients. Staab reported that the present
Röche assay was more specific for CEA isomers from
patients with colon carcinoma than the Röche radio-
immunoassay with polyclonal antiserum (6).
However Buchegger et al. (10) and Oehr et al. (11)
did not observe particular organ specificity with
monoclonal anti-CEA antobodies. In our study üo
clusters of the data from any classified type of carci-
noma were evident (fig. 2, tab. 6).
The only exception was pancreas carcinoma, all our
three patients with advanced metastatic disease giving
higher CEA levels with the Röche assay. However, in
view of the limited number of subjects this aspect
needs further study.
The good general correspondence would imply that
the assay using monoclonal antibody is no more
organ specific than the one using polyclonal antibody.
According to the manufacturer the new double mono-
clonal Abbott assay correlates favourably with the
polyclonal version tested here. Thus, the Röche and
Abbott assays currently available should give equiva-
lent overall results.
In individual cases relatively large differences between
the two methods can be obtained (fig. 3). For instance
case B from figure 3 demons.tjrates that a change of
method from Abbott to Röche at 12 months would
have falsely led to the conclusion that CEA produc-
tion had decreased, whereas it is clear that the oppo-
site is true.
This implies that in order to change from one method
to another a transition period is necessary in every
patient, in order to establish a new baseline. After an
appropriate transition period, the monoclonal EIA
of Röche has been used without problems äs the
routine method for CEA determinations in both au-
thors' laboratories since the summer of 1984.
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